Compare iShares MSCI Singapore ETF (EWS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Mesoblast Limited — how do they compare? iShares MSCI Singapore ETF trades at $31.56 (market cap $1.49B), while Mesoblast Limited trades at $14.31 (market cap $1.75B). The key difference: Mesoblast Limited is the larger of the two by market cap, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 45 Days and Mesoblast Limited for 14 Days on average.
| EWS | MESO | |
|---|---|---|
Market Cap | $1.49B | $1.75B |
Volume | 2,142,305 | 239,027 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $20.96 |
52-Week Low | $26.71 | $13.19 |
Typical Hold Time | 45 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $32.48, down 2.17% amid bearish technical signals. The ETF recently hit a 52-week high, driven by Singapore's economic strength and AI momentum, but faces selling pressure with key support at $32. Financial ratios are unavailable, limiting fundamental clarity.
Outlook remains mixed; Singapore's growth and institutional interest offer upside, but stretched valuations and technical weakness pose risks. Investors should weigh regional economic resilience against potential pullbacks in a volatile market.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
